Merrimack Pharmaceuticals Stock Price, News & Analysis (NASDAQ:MACK)

$11.75 0.10 (0.86 %)
(As of 11/17/2017 04:00 PM ET)
Previous Close$11.65
Today's Range$11.49 - $11.81
52-Week Range$11.14 - $65.90
Volume86,413 shs
Average Volume264,385 shs
Market Capitalization$155.33 million
P/E RatioN/A
Dividend YieldN/A
Beta1.72

About Merrimack Pharmaceuticals (NASDAQ:MACK)

Merrimack Pharmaceuticals logoMerrimack Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing medicines consisting of therapeutics paired with companion diagnostics for the treatment of cancer. The Company has one marketed therapeutic oncology product and multiple targeted therapeutic oncology candidates in clinical development. Its advanced program is its therapeutic MM-398, which it markets in the United States under the brand name ONIVYDE. Its other clinical stage product candidates include MM-121, MM-141, MM-310, MM-302 and MM-151. The Company is developing in vitro and in vivo diagnostics for use with each of its oncology therapeutic product candidates. Its in vitro diagnostic agents employ biophysical or biochemical markers of cancer, or biomarkers. Its in vivo diagnostics take the form of imaging agents that may help identify patients likely to benefit from its therapeutic products by measuring deposition of its products in the tumor.


Industry, Sector and Symbol:
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: Biotechnology
  • Sector: Biotechnology & Medical Research - NEC
  • Symbol: NASDAQ:MACK
  • CUSIP: 59032810
  • Web: www.merrimackpharma.com
Debt:
  • Debt-to-Equity Ratio: 0.45%
  • Current Ratio: 3.35%
  • Quick Ratio: 3.35%
Sales & Book Value:
  • Annual Sales: $144.27 million
  • Price / Sales: 1.09
  • Book Value: $8.37 per share
  • Price / Book: 1.40
Profitability:
  • Trailing EPS: ($7.29)
  • Net Income: ($151,740,000.00)
  • Return on Assets: -68.02%
Misc:
  • Employees: 294
  • Outstanding Shares: 13,330,000
 
Frequently Asked Questions for Merrimack Pharmaceuticals (NASDAQ:MACK)

What is Merrimack Pharmaceuticals' stock symbol?

Merrimack Pharmaceuticals trades on the NASDAQ under the ticker symbol "MACK."

How often does Merrimack Pharmaceuticals pay dividends? What is the dividend yield for Merrimack Pharmaceuticals?

Merrimack Pharmaceuticals announced an annual dividend on Friday, April 7th. Shareholders of record on Wednesday, May 17th will be given a dividend of $10.60 per share on Friday, May 26th. The ex-dividend date is Tuesday, May 30th. View Merrimack Pharmaceuticals' Dividend History.

When did Merrimack Pharmaceuticals' stock split? How did Merrimack Pharmaceuticals' stock split work?

Shares of Merrimack Pharmaceuticals reverse split before market open on Wednesday, September 6th 2017. The 1-10 reverse split was announced on Thursday, August 31st 2017. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, September 5th 2017. An investor that had 100 shares of Merrimack Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

How were Merrimack Pharmaceuticals' earnings last quarter?

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) announced its earnings results on Thursday, August, 4th. The biopharmaceutical company reported ($4.00) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($3.30) by $0.70. The biopharmaceutical company had revenue of $33.70 million for the quarter, compared to the consensus estimate of $33.35 million. The business's quarterly revenue was up 58.3% compared to the same quarter last year. During the same period last year, the business earned ($3.30) EPS. View Merrimack Pharmaceuticals' Earnings History.

Where is Merrimack Pharmaceuticals' stock going? Where will Merrimack Pharmaceuticals' stock price be in 2017?

2 equities research analysts have issued 1 year target prices for Merrimack Pharmaceuticals' shares. Their predictions range from $15.00 to $15.00. On average, they anticipate Merrimack Pharmaceuticals' stock price to reach $15.00 in the next twelve months. View Analyst Ratings for Merrimack Pharmaceuticals.

Who are some of Merrimack Pharmaceuticals' key competitors?

Who are Merrimack Pharmaceuticals' key executives?

Merrimack Pharmaceuticals' management team includes the folowing people:

  • Gary L. Crocker, Chairman of the Board (Age 64)
  • Richard Peters M.D. Ph.D., President, Chief Executive Officer, Director (Age 54)
  • Jean M. Franchi CPA, Chief Financial Officer,Principal Financial Officer, Principal Accounting Officer, Treasurer (Age 50)
  • John L. Green, Controller (Age 37)
  • Ellen K. Forest, Head of Human Resources
  • Sergio L. Santillana, Chief Medical Officer
  • Ulrik B. Nielsen Ph.D., Director (Age 44)
  • John M. Dineen, Independent Director (Age 52)
  • Vivian S. Lee, Independent Director (Age 50)
  • John Mendelsohn M.D., Independent Director (Age 79)

Who owns Merrimack Pharmaceuticals stock?

Merrimack Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Newtyn Management LLC (2.93%), Cannell Peter B & Co. Inc. (0.65%), Bank of New York Mellon Corp (0.52%), Schwab Charles Investment Management Inc. (0.40%), Dimensional Fund Advisors LP (0.19%) and Swiss National Bank (151,462.87%). Company insiders that own Merrimack Pharmaceuticals stock include Birgit M Schoeberl, Daryl C Drummond, Edward J Stewart, Michael E Porter, Ulrik B Nielsen, Vivian S Lee and William M Mcclements. View Institutional Ownership Trends for Merrimack Pharmaceuticals.

Who sold Merrimack Pharmaceuticals stock? Who is selling Merrimack Pharmaceuticals stock?

Merrimack Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Cannell Peter B & Co. Inc., Candriam Luxembourg S.C.A., Bank of New York Mellon Corp, California State Teachers Retirement System, Schwab Charles Investment Management Inc., Swiss National Bank, Brown Advisory Inc. and New York State Common Retirement Fund. Company insiders that have sold Merrimack Pharmaceuticals company stock in the last year include Daryl C Drummond and Ulrik B Nielsen. View Insider Buying and Selling for Merrimack Pharmaceuticals.

Who bought Merrimack Pharmaceuticals stock? Who is buying Merrimack Pharmaceuticals stock?

Merrimack Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Newtyn Management LLC, Dimensional Fund Advisors LP and Macquarie Group Ltd.. Company insiders that have bought Merrimack Pharmaceuticals stock in the last two years include Michael E Porter, Vivian S Lee and William M Mcclements. View Insider Buying and Selling for Merrimack Pharmaceuticals.

How do I buy Merrimack Pharmaceuticals stock?

Shares of Merrimack Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Merrimack Pharmaceuticals' stock price today?

One share of Merrimack Pharmaceuticals stock can currently be purchased for approximately $11.75.

How big of a company is Merrimack Pharmaceuticals?

Merrimack Pharmaceuticals has a market capitalization of $155.33 million and generates $144.27 million in revenue each year. The biopharmaceutical company earns ($151,740,000.00) in net income (profit) each year or ($7.29) on an earnings per share basis. Merrimack Pharmaceuticals employs 294 workers across the globe.

How can I contact Merrimack Pharmaceuticals?

Merrimack Pharmaceuticals' mailing address is 1 Kendall Sq Ste B7201, CAMBRIDGE, MA 02139-1670, United States. The biopharmaceutical company can be reached via phone at +1-617-4411000 or via email at ggrande@merrimack.com.


MarketBeat Community Rating for Merrimack Pharmaceuticals (NASDAQ MACK)
Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  221 (Vote Outperform)
Underperform Votes:  156 (Vote Underperform)
Total Votes:  377
MarketBeat's community ratings are surveys of what our community members think about Merrimack Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Ratings for Merrimack Pharmaceuticals (NASDAQ:MACK) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 2 Hold Ratings, 0 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $15.00 (27.66% upside)
Consensus Price Target History for Merrimack Pharmaceuticals (NASDAQ:MACK)
Price Target History for Merrimack Pharmaceuticals (NASDAQ:MACK)
Analysts' Ratings History for Merrimack Pharmaceuticals (NASDAQ:MACK)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/13/2017Robert W. BairdReiterated RatingHold$15.00N/AView Rating Details
5/19/2017Cowen and CompanyReiterated RatingMarket PerformLowView Rating Details
11/10/2016J P Morgan Chase & CoReiterated RatingHold$70.00N/AView Rating Details
11/10/2016BTIG ResearchReiterated RatingNeutralN/AView Rating Details
8/5/2016Brean CapitalSet Price TargetBuy$160.00 -> $130.00N/AView Rating Details
5/20/2016MizuhoReiterated RatingBuy$130.00N/AView Rating Details
12/30/2015Oppenheimer Holdings, Inc.Reiterated RatingBuyN/AView Rating Details
(Data available from 11/17/2015 forward)

Earnings

Earnings History for Merrimack Pharmaceuticals (NASDAQ:MACK)
Earnings by Quarter for Merrimack Pharmaceuticals (NASDAQ:MACK)
Earnings History by Quarter for Merrimack Pharmaceuticals (NASDAQ MACK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/9/2017Q2 2017($1.37)($2.18)$18.00 millionViewListenView Earnings Details
5/10/2017Q1 2017($0.70)($2.20)$32.16 millionViewN/AView Earnings Details
3/1/2017Q416($2.10)($2.50)$50.44 million$61.20 millionViewListenView Earnings Details
11/9/2016Q316($2.70)($2.30)$41.00 million$28.07 millionViewListenView Earnings Details
8/4/2016Q216($3.30)($4.00)$33.35 million$33.70 millionViewN/AView Earnings Details
5/2/2016Q116($3.80)($3.30)$24.16 million$21.30 millionViewN/AView Earnings Details
2/25/2016Q415($4.10)($4.10)$31.73 million$21.42 millionViewListenView Earnings Details
11/9/2015Q315($4.00)($3.80)$14.04 million$16.44 millionViewN/AView Earnings Details
8/10/2015Q215($3.10)($2.10)$17.57 million$36.60 millionViewListenView Earnings Details
5/7/2015Q1 2015($3.00)($3.20)$14.50 million$14.84 millionViewN/AView Earnings Details
2/26/2015Q4($2.30)($0.90)$25.13 million$33.91 millionViewN/AView Earnings Details
11/10/2014Q3 2014($1.20)($2.70)$61.50 million$28.00 millionViewN/AView Earnings Details
8/11/2014Q2 2014($3.20)($1.70)$10.83 million$27.82 millionViewN/AView Earnings Details
5/1/2014Q114($3.10)($2.70)$11.93 million$13.03 millionViewN/AView Earnings Details
2/27/2014($2.90)($3.30)ViewN/AView Earnings Details
11/7/2013($3.40)($3.90)ViewN/AView Earnings Details
8/8/2013Q2 2013($2.80)($3.10)$13.68 million$18.45 millionViewN/AView Earnings Details
3/14/2013Q4 2012($2.60)($17.60)$11.77 million$12.58 millionViewN/AView Earnings Details
11/14/2012Q312($18.10)$8.60 million$11.30 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Merrimack Pharmaceuticals (NASDAQ:MACK)
Current Year EPS Consensus Estimate: $-2.42 EPS
Next Year EPS Consensus Estimate: $-6.03 EPS

Dividends

Dividend History by Quarter for Merrimack Pharmaceuticals (NASDAQ MACK)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/7/2017Annual$10.605/30/20175/17/20175/26/2017
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Merrimack Pharmaceuticals (NASDAQ MACK)
Insider Ownership Percentage: 8.53%
Insider Trades by Quarter for Merrimack Pharmaceuticals (NASDAQ:MACK)
Institutional Ownership by Quarter for Merrimack Pharmaceuticals (NASDAQ:MACK)
Insider Trades by Quarter for Merrimack Pharmaceuticals (NASDAQ MACK)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/15/2017Ulrik B NielsenDirectorSell7,896$14.23$112,360.08View SEC Filing  
9/14/2017Ulrik B NielsenDirectorSell100$14.20$1,420.00View SEC Filing  
9/13/2017Ulrik B NielsenDirectorSell21,556$14.40$310,406.40View SEC Filing  
9/11/2017Ulrik B NielsenDirectorSell14,756$14.46$213,371.76View SEC Filing  
5/12/2017Daryl C DrummondInsiderSell4,097$3.72$15,240.84View SEC Filing  
7/25/2016Birgit M SchoeberlInsiderSell50,000$5.50$275,000.00View SEC Filing  
3/17/2016Michael E PorterDirectorBuy5,000$7.20$36,000.00View SEC Filing  
3/15/2016Michael E PorterDirectorBuy5,000$7.65$38,250.00View SEC Filing  
3/8/2016Michael E PorterDirectorBuy10,000$7.09$70,900.00View SEC Filing  
3/3/2016Michael E PorterDirectorBuy15,000$6.39$95,850.00View SEC Filing  
3/1/2016Michael E PorterDirectorBuy20,000$6.11$122,200.00View SEC Filing  
2/29/2016Vivian S LeeDirectorBuy35,000$5.50$192,500.00View SEC Filing  
2/29/2016William M McclementsInsiderBuy2,000$5.72$11,440.00View SEC Filing  
1/5/2016Edward J. StewartinsiderSell4,000$8.00$32,000.00View SEC Filing  
12/1/2015Edward J. StewartinsiderSell5,000$9.33$46,650.00View SEC Filing  
11/2/2015Edward J. StewartinsiderSell6,000$9.42$56,520.00View SEC Filing  
10/16/2015Edward J. StewartinsiderSell1,000$10.00$10,000.00View SEC Filing  
10/2/2015Edward J. StewartinsiderSell5,000$8.20$41,000.00View SEC Filing  
9/1/2015Edward J. StewartinsiderSell6,000$9.88$59,280.00View SEC Filing  
8/21/2015Michael E PorterDirectorBuy5,000$9.76$48,800.00View SEC Filing  
8/17/2015Edward J. StewartinsiderSell6,000$10.49$62,940.00View SEC Filing  
8/14/2015Michael E PorterDirectorBuy13,000$10.54$137,020.00View SEC Filing  
7/20/2015Ulrik B NielsenDirectorSell20,000$10.71$214,200.00View SEC Filing  
7/15/2015Edward J StewartInsiderSell6,000$11.84$71,040.00View SEC Filing  
7/15/2015William A SullivanCFOSell15,000$11.85$177,750.00View SEC Filing  
6/19/2015Ulrik B NielsenDirectorSell40,000$12.02$480,800.00View SEC Filing  
6/18/2015Edward J StewartInsiderSell2,000$12.00$24,000.00View SEC Filing  
6/15/2015Edward J StewartInsiderSell6,000$10.67$64,020.00View SEC Filing  
6/15/2015William A SullivanCFOSell15,000$10.65$159,750.00View SEC Filing  
5/19/2015Ulrik B NielsenDirectorSell40,000$13.04$521,600.00View SEC Filing  
5/13/2015Michael E PorterDirectorBuy8,284$11.79$97,668.36View SEC Filing  
4/20/2015Ulrik B NielsenDirectorSell40,000$12.88$515,200.00View SEC Filing  
4/15/2015Edward J StewartSVPSell8,000$12.79$102,320.00View SEC Filing  
4/15/2015William A SullivanCFOSell15,000$12.87$193,050.00View SEC Filing  
4/13/2015Gordon J FehrDirectorSell20,000$13.00$260,000.00View SEC Filing  
3/24/2015Robert J MulroyCEOSell114,368$11.71$1,339,249.28View SEC Filing  
3/23/2015Robert J MulroyCEOSell10,400$11.69$121,576.00View SEC Filing  
3/20/2015Michael E PorterDirectorBuy5,000$11.77$58,850.00View SEC Filing  
3/19/2015Ulrik B NielsenDirectorSell40,000$11.97$478,800.00View SEC Filing  
3/19/2015William A SullivanCFOSell15,000$11.97$179,550.00View SEC Filing  
3/17/2015Birgit M SchoeberlInsiderSell42,234$12.00$506,808.00View SEC Filing  
3/17/2015Edward J StewartSVPSell8,000$11.95$95,600.00View SEC Filing  
3/17/2015Michael E PorterDirectorBuy1,190$11.77$14,006.30View SEC Filing  
3/16/2015Birgit M SchoeberlInsiderSell20,897$12.00$250,764.00View SEC Filing  
3/16/2015Edward J StewartSVPSell6,000$11.93$71,580.00View SEC Filing  
3/11/2015Michael E PorterDirectorBuy5,000$11.33$56,650.00View SEC Filing  
3/2/2015Michael E PorterDirectorBuy5,000$10.93$54,650.00View SEC Filing  
2/23/2015Ulrik B NielsenDirectorSell20,000$10.91$218,200.00View SEC Filing  
2/20/2015Robert J MulroyCEOSell150,000$10.94$1,641,000.00View SEC Filing  
1/15/2015Edward J StewartSVPSell6,000$11.19$67,140.00View SEC Filing  
12/24/2014William A SullivanCFOSell15,000$10.70$160,500.00View SEC Filing  
12/23/2014Vivian S LeeDirectorBuy20,000$10.23$204,600.00View SEC Filing  
12/18/2014Anthony J SinskeyDirectorSell20,000$10.31$206,200.00View SEC Filing  
12/15/2014Edward J StewartSVPSell6,000$10.63$63,780.00View SEC Filing  
12/8/2014Robert J MulroyCEOSell200,000$9.84$1,968,000.00View SEC Filing  
12/2/2014Michael E PorterDirectorBuy8,000$8.71$69,680.00View SEC Filing  
11/21/2014Michael E PorterDirectorBuy11,909$8.87$105,632.83View SEC Filing  
11/18/2014Edward J StewartSVPSell5,000$8.55$42,750.00View SEC Filing  
11/14/2014Michael E PorterDirectorBuy5,000$8.29$41,450.00View SEC Filing  
11/13/2014Gary L CrockerDirectorBuy14,390$8.47$121,883.30View SEC Filing  
11/12/2014Michael E PorterDirectorBuy40,000$8.37$334,800.00View SEC Filing  
10/23/2014Edward J StewartSVPSell3,000$9.05$27,150.00View SEC Filing  
9/30/2014William A SullivanCFOSell105,282$8.61$906,478.02View SEC Filing  
9/29/2014William A SullivanCFOSell64,404$8.40$540,993.60View SEC Filing  
9/24/2014Edward J StewartSVPSell12,000$8.22$98,640.00View SEC Filing  
6/23/2014Gary L CrockerDirectorBuy36,000$6.84$246,240.00View SEC Filing  
5/20/2014Gary CrockerDirectorBuy4,000$6.69$26,760.00View SEC Filing  
5/19/2014Gary CrockerDirectorBuy9,400$6.68$62,792.00View SEC Filing  
5/16/2014Michael PorterDirectorBuy15,000$6.49$97,350.00View SEC Filing  
5/13/2014Anthony SinskeyDirectorBuy5,000$6.74$33,700.00View SEC Filing  
5/8/2014Michael PorterDirectorBuy10,000$6.59$65,900.00View SEC Filing  
5/7/2014Gary CrockerDirectorBuy4,400$6.77$29,788.00View SEC Filing  
5/6/2014Gary CrockerDirectorBuy17,500$6.89$120,575.00View SEC Filing  
5/5/2014Michael PorterDirectorBuy15,000$6.41$96,150.00View SEC Filing  
5/5/2014Robert MulroyCEOBuy5,000$6.31$31,550.00View SEC Filing  
12/17/2013Michael PorterDirectorBuy25,000$4.75$118,750.00View SEC Filing  
12/12/2013William McclementsSVPBuy4,000$4.26$17,040.00View SEC Filing  
12/10/2013Michael PorterDirectorBuy18,000$4.38$78,840.00View SEC Filing  
12/6/2013James QuigleyDirectorBuy39,000$4.70$183,300.00View SEC Filing  
12/4/2013Robert MulroyCEOBuy33,100$4.42$146,302.00View SEC Filing  
12/3/2013Sarah NashDirectorBuy47,500$4.17$198,075.00View SEC Filing  
12/2/2013William McclementsSVPBuy2,000$4.06$8,120.00View SEC Filing  
11/29/2013Anthony SinskeyDirectorBuy3,800$3.92$14,896.00View SEC Filing  
11/27/2013Gary CrockerDirectorBuy207,000$3.72$770,040.00View SEC Filing  
12/14/2012John MendelsohnDirectorBuy5,000$6.63$33,150.00View SEC Filing  
12/13/2012Gary L CrockerDirectorBuy36,500$6.77$247,105.00View SEC Filing  
12/10/2012Michael E PorterDirectorBuy10,000$6.08$60,800.00View SEC Filing  
9/14/2012Gary L CrockerDirectorBuy64,800$8.33$539,784.00View SEC Filing  
8/24/2012James H QuigleyDirectorBuy12,500$7.55$94,375.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Merrimack Pharmaceuticals (NASDAQ:MACK)
Latest Headlines for Merrimack Pharmaceuticals (NASDAQ MACK)
Source:
DateHeadline
Merrimack Pharmaceuticals, Inc. (MACK) Expected to Post Quarterly Sales of $24.00 MillionMerrimack Pharmaceuticals, Inc. (MACK) Expected to Post Quarterly Sales of $24.00 Million
www.americanbankingnews.com - November 11 at 6:40 AM
 Analysts Anticipate Merrimack Pharmaceuticals, Inc. (MACK) Will Announce Earnings of -$1.30 Per Share Analysts Anticipate Merrimack Pharmaceuticals, Inc. (MACK) Will Announce Earnings of -$1.30 Per Share
www.americanbankingnews.com - November 9 at 1:44 PM
Edited Transcript of MACK earnings conference call or presentation 8-Nov-17 1:30pm GMTEdited Transcript of MACK earnings conference call or presentation 8-Nov-17 1:30pm GMT
finance.yahoo.com - November 8 at 9:39 PM
Merrimack Reports Third Quarter 2017 Financial Results - PR Newswire (press release)Merrimack Reports Third Quarter 2017 Financial Results - PR Newswire (press release)
www.prnewswire.com - November 8 at 4:38 PM
Merrimack Pharmaceuticals, Inc. to Host Earnings CallMerrimack Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - November 8 at 4:38 PM
Merrimack Reports Third Quarter 2017 Financial ResultsMerrimack Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 8 at 4:38 PM
Merrimack's (MACK) Reports Narrower-than-Expected Q3 LossMerrimack's (MACK) Reports Narrower-than-Expected Q3 Loss
finance.yahoo.com - November 8 at 4:38 PM
Merrimack beats 3Q profit forecastsMerrimack beats 3Q profit forecasts
finance.yahoo.com - November 8 at 4:38 PM
What's in the Cards for Merrimack (MACK) in Q3 Earnings?What's in the Cards for Merrimack (MACK) in Q3 Earnings?
finance.yahoo.com - November 7 at 6:37 AM
Merrimack Announces Timing of Third Quarter 2017 Investor Conference CallMerrimack Announces Timing of Third Quarter 2017 Investor Conference Call
finance.yahoo.com - November 2 at 6:12 AM
Merrimack Announces Timing of Third Quarter 2017 Investor Conference Call - PR Newswire (press release)Merrimack Announces Timing of Third Quarter 2017 Investor Conference Call - PR Newswire (press release)
www.prnewswire.com - November 2 at 6:12 AM
Merrimack Pharmaceuticals, Inc. (MACK) Set to Announce Earnings on TuesdayMerrimack Pharmaceuticals, Inc. (MACK) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - October 31 at 8:36 AM
Merrimack Receives Orphan Drug Designation for MM-121 for the Treatment of Heregulin Positive Non-small Cell Lung CancerMerrimack Receives Orphan Drug Designation for MM-121 for the Treatment of Heregulin Positive Non-small Cell Lung Cancer
finance.yahoo.com - October 31 at 3:14 AM
Merrimack Pharmaceuticals Inc (MACK) Granted FDA Orphan-Drug Designation for MM-121Merrimack Pharmaceuticals Inc (MACK) Granted FDA Orphan-Drug Designation for MM-121
finance.yahoo.com - October 31 at 3:14 AM
Have Investors Already Priced In Merrimack Pharmaceuticals Inc’s (MACK) Growth?Have Investors Already Priced In Merrimack Pharmaceuticals Inc’s (MACK) Growth?
finance.yahoo.com - October 29 at 6:35 AM
Merrimack Pharmaceuticals, Inc. (MACK) Receives Consensus Rating of "Hold" from AnalystsMerrimack Pharmaceuticals, Inc. (MACK) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - October 26 at 1:56 PM
Merrimack Pharmaceuticals (MACK) Hold Rating Reaffirmed at Robert W. BairdMerrimack Pharmaceuticals' (MACK) Hold Rating Reaffirmed at Robert W. Baird
www.americanbankingnews.com - October 14 at 10:12 PM
Merrimack Commences Tender Offer for Any and All of its Outstanding 4.50% Convertible Senior Notes Due 2020 - PR Newswire (press release)Merrimack Commences Tender Offer for Any and All of its Outstanding 4.50% Convertible Senior Notes Due 2020 - PR Newswire (press release)
www.prnewswire.com - October 14 at 2:26 AM
Merrimack Commences Tender Offer for Any and All of its Outstanding 4.50% Convertible Senior Notes Due 2020Merrimack Commences Tender Offer for Any and All of its Outstanding 4.50% Convertible Senior Notes Due 2020
finance.yahoo.com - October 14 at 2:26 AM
Merrimack Pharma (MACK) Settles Convertible Note LitigationMerrimack Pharma (MACK) Settles Convertible Note Litigation
www.streetinsider.com - October 12 at 6:44 AM
Merrimack Pharmaceuticals Inc (MACK): How Does It Impact Your Portfolio?Merrimack Pharmaceuticals Inc (MACK): How Does It Impact Your Portfolio?
finance.yahoo.com - October 11 at 1:09 AM
BRIEF-Merrimack announces settlement of convertible note litigationBRIEF-Merrimack announces settlement of convertible note litigation
www.reuters.com - October 10 at 8:06 PM
Merrimack Announces Settlement of Convertible Note LitigationMerrimack Announces Settlement of Convertible Note Litigation
finance.yahoo.com - October 10 at 8:06 PM
Oncorus®, Inc., Names Christophe Quéva, Ph.D., as Chief Scientific ... - PR Newswire (press release)Oncorus®, Inc., Names Christophe Quéva, Ph.D., as Chief Scientific ... - PR Newswire (press release)
www.prnewswire.com - October 4 at 6:35 AM
Merrimack Pharmaceuticals, Inc. (MACK) Receives Average Recommendation of "Hold" from AnalystsMerrimack Pharmaceuticals, Inc. (MACK) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - October 1 at 2:40 PM
Ex-Akebia employee suspected of insider trading re-arrested - ReutersEx-Akebia employee suspected of insider trading re-arrested - Reuters
www.reuters.com - September 24 at 1:04 AM
Ex-Akebia employee suspected of insider trading re-arrested - Reuters - ReutersEx-Akebia employee suspected of insider trading re-arrested - Reuters - Reuters
www.reuters.com - September 23 at 8:00 AM
Is It Time To Buy Merrimack Pharmaceuticals Inc (MACK)?Is It Time To Buy Merrimack Pharmaceuticals Inc (MACK)?
finance.yahoo.com - September 21 at 5:34 PM
Merrimack Pharmaceuticals, Inc. (MACK) Director Ulrik B. Nielsen Sells 7,896 SharesMerrimack Pharmaceuticals, Inc. (MACK) Director Ulrik B. Nielsen Sells 7,896 Shares
www.americanbankingnews.com - September 15 at 8:02 PM
Merrimack Pharmaceuticals, Inc. (MACK) Short Interest Down 4.2% in AugustMerrimack Pharmaceuticals, Inc. (MACK) Short Interest Down 4.2% in August
www.americanbankingnews.com - September 15 at 1:02 AM
Merrimack Pharmaceuticals, Inc. (MACK) Director Sells $213,371.76 in StockMerrimack Pharmaceuticals, Inc. (MACK) Director Sells $213,371.76 in Stock
www.americanbankingnews.com - September 13 at 8:28 PM
Insider Selling: Merrimack Pharmaceuticals, Inc. (MACK) Director Sells 21,556 Shares of StockInsider Selling: Merrimack Pharmaceuticals, Inc. (MACK) Director Sells 21,556 Shares of Stock
www.americanbankingnews.com - September 13 at 8:28 PM
Verastem Shares Are Exploding 50% -- Heres WhyVerastem Shares Are Exploding 50% -- Here's Why
www.msn.com - September 7 at 12:52 AM
BRIEF-Merrimack announces date of one-for-ten reverse stock splitBRIEF-Merrimack announces date of one-for-ten reverse stock split
www.reuters.com - September 2 at 6:04 AM
Merrimack Pharma (MACK) One-for-Ten Reverse Stock Split ... - StreetInsider.comMerrimack Pharma (MACK) One-for-Ten Reverse Stock Split ... - StreetInsider.com
www.streetinsider.com - September 1 at 3:24 AM
Merrimack Announces Date of One-for-Ten Reverse Stock SplitMerrimack Announces Date of One-for-Ten Reverse Stock Split
finance.yahoo.com - September 1 at 3:24 AM
Otonomy Shares Rebound After Wednesdays Drop- Biotech MoversOtonomy Shares Rebound After Wednesday's Drop- Biotech Movers
finance.yahoo.com - September 1 at 3:24 AM
Form 8-K MERRIMACK PHARMACEUTICAL For: Aug 10 - StreetInsider.comForm 8-K MERRIMACK PHARMACEUTICAL For: Aug 10 - StreetInsider.com
www.streetinsider.com - August 15 at 1:18 AM
BRIEF-Merrimack Pharmaceuticals names Jean Franchi CFO - ReutersBRIEF-Merrimack Pharmaceuticals names Jean Franchi CFO - Reuters
www.reuters.com - August 15 at 1:17 AM
Merrimack Augments Executive Team with Appointment of Jean Franchi as Chief Financial OfficerMerrimack Augments Executive Team with Appointment of Jean Franchi as Chief Financial Officer
finance.yahoo.com - August 15 at 1:17 AM
Merrimack Pharmaceuticals, Inc. (MACK) Given Average Recommendation of "Hold" by BrokeragesMerrimack Pharmaceuticals, Inc. (MACK) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - August 12 at 2:50 PM
Merrimack (MACK) Q2 Loss Wider than Expected, Stock FallsMerrimack (MACK) Q2 Loss Wider than Expected, Stock Falls
finance.yahoo.com - August 11 at 6:18 AM
Merrimacks (MACK) Reports Wider-than-Expected Q2 Loss - NasdaqMerrimack's (MACK) Reports Wider-than-Expected Q2 Loss - Nasdaq
www.nasdaq.com - August 10 at 4:03 AM
Merrimack Reports Second Quarter 2017 Financial Results - PR Newswire (press release)Merrimack Reports Second Quarter 2017 Financial Results - PR Newswire (press release)
www.prnewswire.com - August 10 at 4:03 AM
Merrimack Reports Second Quarter 2017 Financial ResultsMerrimack Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 10 at 4:03 AM
Merrimack's (MACK) Reports Wider-than-Expected Q2 LossMerrimack's (MACK) Reports Wider-than-Expected Q2 Loss
finance.yahoo.com - August 10 at 4:03 AM
Merrimack misses 2Q profit forecastsMerrimack misses 2Q profit forecasts
finance.yahoo.com - August 10 at 4:03 AM
Edited Transcript of MACK earnings conference call or presentation 9-Aug-17 12:30pm GMTEdited Transcript of MACK earnings conference call or presentation 9-Aug-17 12:30pm GMT
finance.yahoo.com - August 10 at 4:03 AM
Merrimack Pharmaceuticals Inc (MACK) Announces  Earnings Results, Misses Expectations By $0.08 EPSMerrimack Pharmaceuticals Inc (MACK) Announces Earnings Results, Misses Expectations By $0.08 EPS
www.americanbankingnews.com - August 9 at 5:32 PM
Ewing Sarcoma Therapeutics Pipeline Analysis 2017 - Key Players are Pfizer Inc., Merrimack Pharmaceuticals & Celldex TherapeuticsEwing Sarcoma Therapeutics Pipeline Analysis 2017 - Key Players are Pfizer Inc., Merrimack Pharmaceuticals & Celldex Therapeutics
www.prnewswire.com - August 4 at 1:11 AM

Social Media

Financials

Chart

Merrimack Pharmaceuticals (NASDAQ MACK) Chart for Friday, November, 17, 2017
Loading chart…

This page was last updated on 11/17/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.